• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with Coronavirus Disease 2019

tetano

Editor, Senior Moderator
J Med Virol


. 2020 Jul 16.
doi: 10.1002/jmv.26307. Online ahead of print.
Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with Coronavirus Disease 2019


Weiyin Lin[SUP] 1 [/SUP], Zhiwei Xie[SUP] 2 [/SUP], Yueping Li[SUP] 2 [/SUP], Liya Li[SUP] 3 [/SUP], Chunyan Wen[SUP] 1 [/SUP], Yi Cao[SUP] 1 [/SUP], Xiaoting Chen[SUP] 1 [/SUP], Xu Ou[SUP] 1 [/SUP], Fengyu Hu[SUP] 3 [/SUP], Feng Li[SUP] 3 [/SUP], Xiaoping Tang[SUP] 3 [/SUP], Weiping Cai[SUP] 1 [/SUP], Linghua Li[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA was found in intestines and feces, but its clinical significance is not completely clear. We aim to characterize the longitudinal test results of SARS-CoV-2 RNA in anal swabs, and to explore the association with disease severity.
Methods: We included laboratory-confirmed Coronavirus Disease 2019 (COVID-19) patients who hospitalized in Guangzhou Eighth People's Hospital and excluded those who had not received anal swabs for SARS-COV-2 RNA testing. Epidemiological, clinical and laboratory data were obtained. Throat swabs and anal swabs were collected periodically for SARS-COV-2 RNA detection.
Results: 217 eligible patients (median aged 50 years, 50.2% were females) were analyzed. 21.2% (46/217) of the patients were detectable for SARS-CoV-2 RNA in anal swabs. The duration of viral RNA was longer, but the viral load was lower in anal swabs than throat swabs in the early stage of disease. During a median follow-up of 20 days, 30 (13.8%) patients admitted to intensive care unit (ICU) for high-flow nasal cannula or higher-level oxygen support measures to correct hypoxemia. Detectable viral RNA in anal swabs (adjusted hazard ratio [aHR], 2.50; 95% CI, 1.20-5.24), increased CRP (aHR, 3.14; 95% CI, 1.35-7.32) and lymphocytopenia (aHR, 3.12; 95% CI, 1.46-6.67) were independently associated with ICU admission. The cumulative incidence of ICU admission was higher among patients with detectable viral RNA in anal swabs (26.3% vs. 10.7%, P=0.006).
Conclusion: Detectable SARS-CoV-2 RNA in the digestive tract was a potential warning indicator of severe disease. This article is protected by copyright. All rights reserved.

Keywords: Anal swab; COVID-19; Disease severity; SARS-CoV-2 RNA.
 
Back
Top Bottom